Pin12 the Cost-Effectiveness Analysis of Entecavir in the Treatment of Chronic Hepatitis B (Chb) Patients in Poland

Orlewska, Ewa; Cerri, KH; Kutikova, Lucie; Yuan, Yongfang; Iloeje, Uchenna H.; Hay, JW

doi:10.1016/s1098-3015(10)69033-x

Cited by 6 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The ICERs we report for treating non-cirrhotic patients are less favorable compared with those reported in other costeffectiveness analyses, often company sponsored (8)(9)(10)(11)(12)(13)(14)(15)(16)(17). How can these differences be explained?…”

Section: Discussionmentioning

confidence: 66%

“…Most models on entecavir (9)(10)(11)(12) and some other models (17;21) assume high treatment effects both for progression to cirrhosis and HCC and calibrate these effects using baseline viral load levels obtained in an untreated community cohort consisting mainly of e antigen negative patients in Taiwan (22;23). It remains to be demonstrated that treatment-induced lowering of viral load results in a long-term reduction of cirrhosis and HCC to a level that is identical to a natural state of low viral load.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Should Chronic Hepatitis B Be Treated as Early as Possible?

Hulstaert

Schwierz

Nevens

et al. 2013

Int J Technol Assess Health Care

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 66%

Section: Discussionmentioning

confidence: 99%

Should Chronic Hepatitis B Be Treated as Early as Possible?

Hulstaert

Schwierz

Nevens

et al. 2013

Int J Technol Assess Health Care

View full text Add to dashboard Cite

show abstract

“…Several studies have been carried out overseas on the cost effectiveness of entecavir in the treatment of HBV patients. Entecavir has been found to be a cost‐effective therapy in studies based in Poland, Sweden, Spain, Hong Kong, China and the United States 15,23 . The Polish study uses some of the data from the REVEAL‐HBV study, which is a Taiwanese‐based study of the largest natural history cohort study in patients with CHB 24 .…”

Section: Discussionmentioning

confidence: 99%

Hepatitis B status in migrants and refugees: increasing health burden in Western Australia

Subramaniam¹,

Flexman

Tarquinio³

et al. 2012

Internal Medicine Journal

View full text Add to dashboard Cite

show abstract

“…The data of 2014 were obtained by adapting the 2009 costs to a 3 % discount rate [ 21 ] (Table 5 ). The transition risks according to the plasma HBV DNA levels and the inter-transition of the complications and the mortality rates were taken from the published studies in the application of the complication costs to the treatment strategies [ 11 – 17 , 19 , 24 – 26 ].…”

Section: Methodsmentioning

confidence: 99%

Cost-effectiveness analysis of oral anti-viral drugs used for treatment of chronic hepatitis B in Turkey

Kockaya¹,

Kose²,

Yenilmez³

et al. 2015

Cost Eff Resour Alloc

View full text Add to dashboard Cite

BackgroundAll international guidelines suggested that Tenofovir and Entecavir are the primary drugs at the first line therapy for the treatment of chronic hepatitis B (CHB). However, in Turkey these medications reimbursed at the second line therapy according to the Healthcare Implementation Notification. The aim of this study is to compare the cost effectiveness of oral antiviral treatment strategies in CHB for Turkey using lamuvidine, telbuvidine, entecavir, and tenofovir as medications.MethodsThe analysis was conducted using Markov models. The analysis scenarios based on first line treatment options with Lamuvidine, Telbuvidine, Entecavir, and Tenofovir as the medications. In the analysis, inadequate response or resistance after receiving 12 months of the treatment with Entecavir and Telbivudine were compared to the results found from switching from Entecavir to Tenofovir or from switching from Telbuvidine to Tenofovir. In additional, inadequate response or resistance after receiving 6 months of the treatment for Lamivudine was compared to the results found from switching from Lamivudine to Tenofovir. The study population included men and women, who were 40 years of age. The patients` compliance was estimated 100 % for all of the therapy options. The model duration was constructed to evaluate, treatment strategy duration of 40 years. The cost of medications, examinations/follow-ups and complications were included in the model. Years of Potential Life Lost was used as the health outcome. An incremental cost-effectiveness ratio analysis has been conducted.Results and discussionWhile the minimum years of life lost was found as 0.22 with tenofovir treatment in 5 years, treatment cost was calculated as 12,169 TL. These values were detected as 0.56 years and 7727 TL, 0.37 years and 12,770 TL, respectively for lamuvidine and telbuvidine treatments. The maximum years of life lost and treatment cost was with lamuvidine treatment were detected as 1.60 years and 18,813 TL and, secondly 0.89 years and 24,007 TL for lamuvidine-tenofovir treatment during 10 years. The minimum years of life lost and cost are 0.54 year and 35,821 TL for tenofovir treatment during 10 years. The minimum years of life lost and cost were determined as 1.21 years and 52,839 TL for tenofovir treatment strategy during 20 years. During 30 years period, tenofovir treatment was found to have the minimum years of life lost (1.73 years) and minimum cost (84,149 TL). When the results of 40 years period were analyzed, years of life lost and costs are 2.06 years and 119,604 TL, 2.13 years and 162,115 TL, 2.13 years and 161,642 TL, 6.52 years and 147,245 TL, 3.20 years and 132,157 TL, 4.10 years and 151,059 TL and 3.05 years and 138,182 TL for tenofovir, entecavir, entecavir-tenofovir, lamuvidine, lamuvidine-tenofovir, telbivudine and telbivudine-tenofovir.ConclusionsIn the model presented in this study, in cost effectiveness analysis about CHB treatments, Tenofovir was found to be one of the cost effective methods in comparison with other treatment strategie...

show abstract

Pin12 the Cost-Effectiveness Analysis of Entecavir in the Treatment of Chronic Hepatitis B (Chb) Patients in Poland

Cited by 6 publications

References 0 publications

Should Chronic Hepatitis B Be Treated as Early as Possible?

Should Chronic Hepatitis B Be Treated as Early as Possible?

Hepatitis B status in migrants and refugees: increasing health burden in Western Australia

Cost-effectiveness analysis of oral anti-viral drugs used for treatment of chronic hepatitis B in Turkey

Contact Info

Product

Resources

About